Last update Aug. 28, 2020
Very Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Candesartan Cilexetil in other languages or writings:
Candesartan Cilexetil belongs to this group or family:
Main tradenames from several countries containing Candesartan Cilexetil in its composition:
|Oral Bioavail.||14 - 40||%|
|Tmax||3 - 4||hours|
|Theoretical Dose||0.0001 - 0.00038||mg/Kg/d|
|Relative Dose||0.07 - 0.1||%|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is an angiotensin II receptor antagonist with actions similar to those of losartan.
It is indicated in the treatment of hypertension and in heart failure.
Oral administration once or twice a day.
Its pharmacokinetic data (high molecular weight and high percentage of plasma protein binding) explain the negligible passage into milk observed (Coberger 2019).
The plasma levels of infants whose mothers take candesartan were indetectable (Coberger 2019).
Its low oral bioavailability makes difficult the absorption towards the infant's plasma from ingested milk, except in prematures or newborns who may show an increased absorption.